US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

20.05

+0.20001.01%

Pre-market: 20.220.1700+0.85%07:06 EDT

Volume:394.18K

Turnover:7.83M

Market Cap:578.34M

PE:32.34

High:20.12

Open:19.78

Low:19.35

Close:19.85

Loading ...

Overview Company News Filings

Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up

FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss

Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA

J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use

4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now

Leerink Partners Keeps Their Buy Rating on Castle Biosciences (CSTL)

Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study

AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer

NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts

Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSTL/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSTL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","market":"US","secType":"STK","nameCN":"Castle Biosciences, Inc.","latestPrice":20.05,"timestamp":1746043200000,"preClose":19.85,"halted":0,"volume":394178,"hourTrading":{"tag":"盘前","latestPrice":20.22,"preClose":20.05,"latestTime":"07:06 EDT","volume":417,"amount":8603.860920000001,"timestamp":1746097608272},"delay":0,"floatShares":26497706,"shares":28844937,"eps":0.62,"marketStatus":"Pre-Mkt","change":0.2,"latestTime":"05-01 07:08:20 EDT","open":19.78,"high":20.12,"low":19.35,"amount":7834975.59061,"amplitude":0.038791,"askPrice":22.99,"askSize":1,"bidPrice":16,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.62,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746106200000},"marketStatusCode":1,"adr":0,"listingDate":1564027200000,"exchange":"NASDAQ","adjPreClose":20.05,"preHourTrading":{"tag":"盘前","latestPrice":20.22,"preClose":20.05,"latestTime":"07:06 EDT","volume":417,"amount":8603.860920000001,"timestamp":1746097608272},"postHourTrading":{"tag":"盘后","latestPrice":20.05,"preClose":20.05,"latestTime":"19:35 EDT","volume":13819,"amount":277071.19,"timestamp":1746056130891},"volumeRatio":0.9186246987483594,"impliedVol":0.5805,"impliedVolPercentile":0.249},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","floatShares":26497706,"roa":"1.10%","roe":"4.31%","lyrEps":0.656862,"volumeRatio":0.9186246987483594,"shares":28844937,"dividePrice":0,"high":20.12,"amplitude":0.038791,"preClose":19.85,"low":19.35,"week52Low":16.965,"pbRate":"1.27","psRate":"1.74","week52High":35.84,"institutionHeld":0,"latestPrice":20.05,"committee":0.980198,"eps":0.62,"divideRate":0,"volume":394178,"delay":0,"ttmEps":0.62,"open":19.78,"prevYearClose":26.65,"prevWeekClose":20.63,"prevMonthClose":20.05,"prevQuarterClose":20.02,"fiveDayClose":21.27,"twentyDayClose":19.78,"sixtyDayClose":28.75,"earningDate":1746374400000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSTL\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507655586","title":"Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2507655586","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507655586?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:55","pubTimestamp":1738162505,"startTime":"0","endTime":"0","summary":"Shares of Castle Biosciences, Inc.  have gained 1.5% over the past four weeks to close the last trading session at $27.06, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $41 indicates a potential upside of 51.5%.However, an impressive consensus price target is not the only factor that indicates a potential upside in CSTL. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-think-castle-145505452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4196"],"gpt_icon":0},{"id":"2507542821","title":"SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2507542821","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507542821?lang=en_us&edition=fundamental","pubTime":"2025-01-29 00:54","pubTimestamp":1738083240,"startTime":"0","endTime":"0","summary":"Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE.Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders.SAGE’s board of directors has now started exploring strategic alternatives and evaluating other options to maximize its shareholders’ value.Shares of SAGE were up 4.8% on Jan. 27 following the news announcement.In the past year, the stock has plunged 72% compared with the industry’s decline of 12.4%.Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan. 10.Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the company.Some better-ranked stocks in the biotech sector are Harmony Biosciences ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-rejects-biogens-offer-buy-165400180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIIB","LU0320765992.SGD","BK4196","LU0889565916.HKD","LU0109394709.USD","SAGE","BK4532","BK4585","BK4530","IE00B894F039.SGD","CSTL","BK4007","BK4144","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","LU0234570918.USD","BK4533","MCI","ET","BK4588","BK4561","PPD","BK4590","HRMY","BK4139","BK4121","BK4581"],"gpt_icon":0},{"id":"2507611549","title":"FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2507611549","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507611549?lang=en_us&edition=fundamental","pubTime":"2025-01-29 00:11","pubTimestamp":1738080660,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application  seeking approval for expanded use of Enhertu  for HER2-low metastatic breast cancer in the United States. The approval of the added indication has triggered a $175 million milestone payment from AstraZeneca to Daiichi Sankyo.The companies’ sBLA was seeking approval for Enhertu to treat unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one endocrine therapy in the metastatic setting.The nod in the United States expands the approved indication of Enhertu in HER2-low metastatic breast cancer to include use in an earlier disease setting as well as in a broader patient population that includes HER2-ultralow. The drug has earlier received the FDA’s Breakthrough Therapy designation in the United States for this new indication.In three months, shares of AstraZeneca have lost 6.8% compared with th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-label-azns-enhertu-161100900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4196","BK4585","BK4007","BMRN","LU2456880835.USD","IE00B19Z3581.USD","BK4566","AZN","LU2236285917.USD","BK4231","LU1829250122.USD","ALNY","IE00B19Z3B42.SGD","CSTL","PFS","DSKYF","BK4139","LU0320765992.SGD","IE00B7SZLL34.SGD","IE0002270589.USD","BK4588","BK4568","LU2462157665.USD","BK4080","DSNKY","LU0109394709.USD","BK4195","LU2417539215.USD","BK4211","LU0889565916.HKD","ADC"],"gpt_icon":0},{"id":"2507543472","title":"PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2507543472","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507543472?lang=en_us&edition=fundamental","pubTime":"2025-01-28 23:22","pubTimestamp":1738077720,"startTime":"0","endTime":"0","summary":"Shares of Pfizer PFE rose nearly 3% on Monday following a report issued by Bloomberg, which stated that activist investor Starboard did not nominate any director to Pfizer’s board ahead of Jan. 25.With the expiry of the deadline, Starboard has foregone an opportunity to bring changes in PFE’s board. This signals a less confrontational approach, at least for this year. Shareholders are set to convene at Pfizer’s annual meeting in April to vote on director seats for the year.The article, however, pointed out that Starboard could still try to make the changes in Pfizer’s board next year if the two parties are unable to reach an agreement.Bloomberg claims to have contacted both Pfizer and Starboard, who have either declined to comment on the above news or are yet to respond.The above article provides some respite to Pfizer’s management, which was accused last year by Starboard of making poor capital allocation, research and development (R&D) failures and problems with forecasting and budge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfe-stock-rises-reports-averting-152200714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0868494617.USD","LU0225771236.USD","BK4585","LU0234572021.USD","BK4196","LU0321505868.SGD","BK4568","LU1894683264.USD","LU0985481810.HKD","ERAS","LU0170899867.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU0058720904.USD","BK4007","BK4533","LU1023059063.AUD","SG9999011175.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","LU0122379950.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","SG9999002224.SGD","IE0002270589.USD","SG9999001176.USD","LU0289739699.SGD","LU1883839398.USD","SG9999003800.SGD","BK4599","IE00B19Z3581.USD","BK4550","CTMX","BK4588","LU0456855351.SGD","PFE","SG9999013999.USD","BK4139","LU1066051498.USD","LU1894683348.USD","BK4592","BK4534","CSTL","LU0306807586.USD","LU1057294990.SGD","SG9999002232.USD","LU0225284248.USD","SG9999001176.SGD","BK4539"],"gpt_icon":0},{"id":"2506304692","title":"NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2506304692","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506304692?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:52","pubTimestamp":1737989520,"startTime":"0","endTime":"0","summary":"Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage study of its investigational candidate, amycretin, in 125 overweight/obese patients. Amycretin is NVO’s unimolecular GLP-1 and amylin receptor agonist intended for once-weekly subcutaneous administration.The phase Ib/IIa study evaluated the safety, tolerability, pharmacokinetics and proof-of-conceptof three doses of amycretin in obesity patients for a total treatment duration of up to 36 weeks.Per Novo Nordisk, the study's primary safety endpoint was met as amycretin demonstrated a safety profileconsistent with incretin-based therapies. Treatment-related adverse events were mostly mild to moderate in severity.NVO shares have plunged 21.7% in the past three months compared with the industry’s 12.2% decline.Detailed Results From the Obesity Study of NVO’s Amycretin. Some better-ranked stocks from the sector areCastle BiosciencesCSTL, BioMarin Pharmaceutical BMRN ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-stock-rises-obesity-drug-145200349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","CSTL","BK4007","BK4599","BK4139","NVO","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","BK4196","BK4585","BK4588","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","BK4548","IE00B19Z3B42.SGD","ALNY","IE00B19Z3581.USD","IE0002270589.USD","BK4566","BMRN","LU1093756325.SGD"],"gpt_icon":1},{"id":"2506893089","title":"Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2506893089","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506893089?lang=en_us&edition=fundamental","pubTime":"2025-01-24 23:56","pubTimestamp":1737734160,"startTime":"0","endTime":"0","summary":"Shares of Anavex Life Sciences AVXL, a clinical-stage biotech making medicines to treat central nervous system  diseases, have skyrocketed 94.7% in the past three months due to recent pipeline successes.Anavex Life Sciences’ clinical developmental pipeline includes two candidates, ANAVEX 2-73  and ANAVEX 3-71. Both these candidates are being developed in separate studies across various stages of development to treat a plethora of CNS indications like Alzheimer’s disease , Parkinson’s disease and schizophrenia, among others.AVXL shares have rallied 53.6% in the past year against the industry’s 12.4% decline.Upbeat Initial Data From AVXL’s Schizophrenia Study. In October 2024, Anavex Life Sciences reported positive initial biomarker results from Part A of an ongoing mid-stage study of ANAVEX 3-71 for schizophrenia. This multiple ascending dose portion of the phase II ANAVEX 3-71-SZ-001 study, evaluated two oral, daily doses of the candidate  in 16 patients for 10 days.The MAA submission ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anavex-life-sciences-stock-skyrockets-155600615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4196","BK4585","BK4215","BK4139","BK4566","CNS","IE00B19Z3581.USD","AVXL","BK4135","IE00B7SZLL34.SGD","MAA","IE0002270589.USD","BK4588","ALNY","IE00B19Z3B42.SGD","CSTL","BMRN"],"gpt_icon":0},{"id":"2506893707","title":"Is it a Good Idea to Invest in Beam Therapeutics Stock Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2506893707","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506893707?lang=en_us&edition=fundamental","pubTime":"2025-01-24 23:40","pubTimestamp":1737733200,"startTime":"0","endTime":"0","summary":"Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease , an inherited blood disorder.BEAM’s pipeline of gene editing therapies is based on its proprietary base editing technology.The company believes that its innovative next-generation technology called base-editing technology can provide a superior way to modify genes and could open up entirely new applications in gene editing, targeting a wide range of severe diseases. It can also make more precise single-base changes at specific locations in genes, resulting in predictable edits in all cells, without needing to damage or make double-stranded breaks in the DNA.Beam Therapeutics currently has a Zacks Rank #2 . In the past 60 days, estimates for BEAM’s 2025 loss per share have narrowed from $4.62 to $4.32.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.58 for 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/good-idea-invest-beam-therapeutics-154000464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4535","CSTL","HRMY","SCD","BK4007","VYGR","BK4196","BK4585","LENZ","BEAM","BK4588","BK4139","BK4556"],"gpt_icon":0},{"id":"2505044214","title":"CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505044214","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505044214?lang=en_us&edition=fundamental","pubTime":"2025-01-24 00:19","pubTimestamp":1737649140,"startTime":"0","endTime":"0","summary":"Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 , a cardiac myosin inhibitor, for treating heart failure patients. The intended patient population includes those with symptomatic heart failure with preserved ejection fraction  with left ventricular ejection fraction  ≥60%.Cytokinetics plans to enroll approximately 60 HFpEF patients in the phase II AMBER-HFpEF study who will receive CK-586 or placebo in three dose escalation cohorts. In the past three months, CYTK shares have lost 10.6% compared with the industry’s 8.7% decline.Cytokinetics is developing its lead investigational candidate, aficamten, a novel, oral and small-molecule cardiac myosin inhibitor, to reduce the hypercontractility associated withhypertrophic cardiomyopathy . A regulatory filing for aficamten to treat obstructive HCM is currently under review by the FDA. A final decision from the regulatory body is expected on Sept. 26, 2025. T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytk-stock-rises-enrollment-begins-161900028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","BK4505","BK4585","CSTL","BK4196","BMRN","IE00B19Z3581.USD","BK4007","BK4531","BK4588","BK4139","BK4566","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","CYTK","HCM","IE0002270589.USD"],"gpt_icon":0},{"id":"2505489620","title":"Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2505489620","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505489620?lang=en_us&edition=fundamental","pubTime":"2025-01-23 22:13","pubTimestamp":1737641580,"startTime":"0","endTime":"0","summary":"Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing in the ongoing mid-stage study of its pipeline candidate, cibotercept , to treat patients with pulmonary arterial hypertension , a kind of lung disease.Keros Therapeutics’ decision was based on unexpected adverse pericardial effusion events that were observed during the study's safety review by an independent data monitoring committee . Cibotercept is an investigational modified ActRIIB fusion protein.The phase II TROPOSstudy is evaluating three doses of cibotercept  in combination with background therapy to treat PAH patients. After consulting with the DMC, Keros Therapeutics initially chose to suspend dosing in the 3 mg/kg and 4.5 mg/kg treatment arms of the TROPOS study while continuing dosing in the 1.5 mg/kg arm. However, earlier this month, the company announced the suspension of dosing i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keros-therapeutics-stock-plunges-81-141300812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KROS","BK4139","IE00B19Z3B42.SGD","CSTL","BMRN","BK4566","BK4196","IE00B7SZLL34.SGD","LENZ","CTMX","IE00B19Z3581.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2505017911","title":"NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2505017911","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505017911?lang=en_us&edition=fundamental","pubTime":"2025-01-23 21:56","pubTimestamp":1737640560,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPRgene editing therapy for the treatment of hereditary angioedema .Shares of the company were up 10.8% on Jan. 22 following the announcement of the news.The global double-blind, placebo-controlled HAELO study will evaluate the safety and efficacy of NTLA-2002 in adults with Type I or Type II HAE. The key endpoint of the study is to see the change in the number of HAE attacks from week five through week 28 of treatment.Enrollment of patients in the study is expected to be completed in the second half of 2025. Intellia plans to submit a biologics license application for NTLA-2002 in HAE in 2026. Upon potential approval, the company plans to launch NTLA-2002 in 2027 in the United States.Despite the current treatment options that require chronic administration for disease control, HAE attacks still occur. NTLA-2002 aims to prevent HAE attacks by ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ntla-begins-dosing-pivotal-study-135600627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BLDYK493.USD","LU2106854487.HKD","REGN","LU0889565916.HKD","LU1169590202.USD","VYGR","LU0109394709.USD","BK4196","NTLA","LU0320765992.SGD","LU0114720955.EUR","BK4198","LU2468319806.SGD","LU0058720904.USD","LU2023250504.SGD","LU0289739699.SGD","LU1169589451.USD","LU0205194284.USD","LU2089984988.USD","LU2362541273.HKD","BK4139","LU2362541513.USD","LU0053666078.USD","BK4556","LU0882574055.USD","LU1917777945.USD","LU0012050646.USD","BK4585","LU0106261612.USD","LU1974910355.USD","CSTL","LU2237438978.USD","HAE","LU1861558580.USD","LU0205193047.USD","LU1861559042.SGD","LU2362540622.SGD","BK4588","LU0823416689.USD","BK4535","IE00B64QTZ34.USD"],"gpt_icon":0},{"id":"2505779089","title":"REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2505779089","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505779089?lang=en_us&edition=fundamental","pubTime":"2025-01-23 00:37","pubTimestamp":1737563820,"startTime":"0","endTime":"0","summary":"Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application  for its lead pipeline candidate, RP1 , in combination with Bristol Myers’ BMY Opdivo  to treat adult patients with advanced melanoma.With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected on July 22, 2025.Shares of REPL were up 16.9% on Jan. 21 following the announcement of the news.The FDA also informed REPL that the agency is not currently planning to hold an advisory committee meeting related to the BLA, as it has not identified any potential review issues at this point.In the past year, shares of Replimune have rallied 50.7% against the industry’s decline of 14.8%.Replimune submitted the BLA for the RP1/Opdivo combo in advanced melanoma in November 2024.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 30.9%.In the past 60 days, es","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/repl-stock-rises-fdas-priority-163700715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868836757.USD","LU0061475181.USD","LU0306807586.USD","LU2242646821.SGD","LU2360032135.SGD","BK4196","IE00B2B36J28.USD","LU0321505868.SGD","LU1571399168.USD","LU1323610961.USD","REPL","LU2125154778.USD","LU0456855351.SGD","LU0882574055.USD","BK4588","BMY","BK4532","LU0868494617.USD","LU0114720955.EUR","LU1868836914.USD","LU2133065610.SGD","LU1430594728.SGD","LU1868837136.USD","BK4581","LU1032466523.USD","LU0237698245.USD","IE0002141913.USD","LU0225771236.USD","IE00BFTCPJ56.SGD","LU0306806265.USD","LU1670711123.USD","LU2125154935.USD","LU1261432733.SGD","BK4534","LU2242652126.USD","LU1291159041.SGD","IE00BSNM7G36.USD","IE0009355771.USD","LU1093756325.SGD","VYGR","LU0321505439.SGD","LU1868837300.USD","LU1670710661.SGD","BK4139","CSTL","LU1670710588.SGD","IE00BJT1NW94.SGD","LU1868836591.USD","LU0225284248.USD","LU1989771016.USD"],"gpt_icon":0},{"id":"2505727779","title":"J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2505727779","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505727779?lang=en_us&edition=fundamental","pubTime":"2025-01-23 00:15","pubTimestamp":1737562500,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application , seeking approval for Spravato  as a monotherapy for adults living with treatment-resistant depression .Spravato is presently approved in combination with an oral antidepressant to treat adults with TRD and depressive symptoms in adults with major depressive disorder  with acute suicidal ideation or behavior.Following the latest nod, Spravato became the first and only monotherapy for treating MDD in adults who have had an inadequate response to at least two oral antidepressants and are considered to have TRD.In the past year, shares of J&J have lost 7.3% compared with the industry’s decline of 5.1%.More on the Latest Nod for JNJ's Spravato as Monotherapy. The latest FDA nod for Spravato was based on data from a double-blind, multicenter, placebo-controlled study.In the past 60 days, estimates for BioMarin’s earnings per share have increased from $3.94 to $4.02 for 2025. In the past year, sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/j-js-depression-drug-spravato-161500318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1718418525.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0882574055.USD","LU2133065610.SGD","LU0795875086.SGD","LU0912757837.SGD","LU0345770308.USD","LU0795875169.SGD","IE00BVYPNV92.GBP","LU0114720955.EUR","LU2468319806.SGD","BK4139","BK4550","LU1280957306.USD","LU2602419157.SGD","LU0792757196.USD","LU1066051811.HKD","SG9999002232.USD","LU0289739699.SGD","LU1261432733.SGD","LU1732800096.USD","BK4566","LU1430594728.SGD","LU1585245621.USD","LU2089984988.USD","VYGR","LU1929549753.HKD","BK4534","BK4559","IE00B19Z3581.USD","LU1221951129.SGD","LU1244550494.USD","LU0203347892.USD","LU1732799900.SGD","BMRN","LU1506573853.SGD","IE00BVYPNW00.USD","IE0009355771.USD","LU0234570918.USD","LU0234572021.USD","LU1066051498.USD","JNJ","BK4532","CSTL","IE0034235303.USD","BK4504","LU0122379950.USD","LU1066051225.USD","IE00BGHQF631.EUR"],"gpt_icon":1},{"id":"2505729014","title":"4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2505729014","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505729014?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:10","pubTimestamp":1737551400,"startTime":"0","endTime":"0","summary":"The primary purpose of a business is to generate profits that can be reinvested in expansion or utilized for rewarding shareholders. Net profit margin is an effective tool to measure the profits reaped by a business.A higher net margin underlines a company’s efficiency in translating sales into actual profits. Moreover, this metric gives insight into how well a company is run and the headwinds weighing on it. Castle Biosciences, Inc. CSTL, OppFi, Inc. OPFI, GigaCloud Technology Inc. GCT and Qifu Technology, Inc. QFIN boast solid net profit margins.In simple terms, net profit is the amount a company retains after deducting all costs, interest, depreciation, taxes and other expenses. In fact, net profit margin can turn out to be a potent point of reference to gauge the strength of a company’s operations and its cost-control measures.Moreover, a higher net profit margin compared with its peers provides a company with a competitive edge.VGM Score of A or B: Our research shows that stocks w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-top-ranked-stocks-solid-131000386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4531","BK4196","BK4585","LU0633140727.USD","LU1981816686.USD","BK4166","LU2476274308.USD","LU2778985437.USD","LU0683595622.HKD","BK4526","CSTL","GCT","BK4588","BK4503","BK4122","LU0633140560.USD","BK4159","OPFI","QFIN","LU1808992512.USD"],"gpt_icon":0},{"id":"2505175023","title":"Leerink Partners Keeps Their Buy Rating on Castle Biosciences (CSTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505175023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505175023?lang=en_us&edition=fundamental","pubTime":"2025-01-22 11:35","pubTimestamp":1737516910,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (CSTL – Research Report) yesterday and set a price target of $5...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-castle-biosciences-cstl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-castle-biosciences-cstl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSTL"],"gpt_icon":0},{"id":"2505204653","title":"Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505204653","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505204653?lang=en_us&edition=fundamental","pubTime":"2025-01-21 23:43","pubTimestamp":1737474180,"startTime":"0","endTime":"0","summary":"NanobiotixNBTX shares were up around 13% during the pre-market hours on Tuesday after the company announced that it has initiated dosing in a mid-stage study evaluating a potential first-in-class radioenhancer, JNJ-1900 , to treat lung cancer patients. The candidate was added to Nanobiotix’s pipeline following a licensing deal for the global co-development and commercialization with pharma bigwig, Johnson & Johnson JNJ, in 2023.The company stated that it has dosed the first patient with JNJ-1900 in the phase II CONVERGE study to treat patients with Stage 3 unresectable non-small cell lung cancer . The eligibility criteria for this study include NSCLC patients receiving standard-of-care chemoradiation followed by consolidation immunotherapy with AstraZeneca’s Imfinzi . Per the global licensing agreement with Nanobiotix, Johnson & Johnson is responsible for funding the CONVERGE study.Nanobiotix’s pipeline comprises only JNJ-1900, which is being evaluated across multiple solid tumor indic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanobiotix-stock-gains-dosing-begins-154300753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B42XCP33.USD","LU1244550494.USD","LU1023059063.AUD","IE00B3PB1722.GBP","NBTX","LU1032466523.USD","BK4139","LU1066051811.HKD","LU1929549753.HKD","SG9999002224.SGD","LU0122379950.USD","BMRN","CSTL","LU0795875169.SGD","JNJ","LU1196500208.SGD","LU0792757196.USD","LU1732800096.USD","LU1674673428.USD","LU0234572021.USD","LU2347655156.SGD","LU1430594728.SGD","SSI","LU0289739699.SGD","IE00BGHQF631.EUR","LU0320765646.SGD","IE00BJT1NW94.SGD","IE0034235303.USD","LU1732799900.SGD","BK4568","LU0882574055.USD","LU1032955483.USD","LU1894683348.USD","BK4532","LU1066051498.USD","LU2602419157.SGD","IE00B4R5TH58.HKD","LU0640476718.USD","IE00BVYPNW00.USD","IE0002270589.USD","LU0889566641.SGD","IE00BDGV0183.EUR","LU1778281490.HKD","LU1935042991.SGD","LU1244550221.USD","BK4550","LU0203345920.USD","IE00B2B36J28.USD","LU0345769128.USD","BK4588"],"gpt_icon":0},{"id":"2505230363","title":"AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505230363","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505230363?lang=en_us&edition=fundamental","pubTime":"2025-01-21 03:05","pubTimestamp":1737399900,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate ,datopotamab deruxtecan , in patients with a certain type of breast cancer. The drug, developed in partnership with Japan-based Daiichi Sankyo, will be marketed under the brand name Datroway.Post the FDA’s approval, the ADC drug is approved to treat unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy.This approval came just a few weeks after Daiichi secured approval for the drug for a similar indication in Japan. The approvals in the United States and Japan are based on data from the phase III TROPION-Breast01 study, which showed that treatment with Datroway significantly reduced the risk of disease progression or death by 37% compared to the investigator’s choice of chemotherapy in the above indication.Per AstraZeneca, Datroway is part of a select group of therapies that could achieve peak annual sales of at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-secures-fda-nod-adc-190500987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","BK4588","BK4231","LU2456880835.USD","LU2462157665.USD","BK4196","ADC","ERAS","BK4007","BK4539","LU0320765992.SGD","LU0889565916.HKD","AZN","CTMX","BK4080","BK4139","CSTL","LU2236285917.USD","LU2417539215.USD","LU0109394709.USD","LU1829250122.USD","BK4585"],"gpt_icon":0},{"id":"2505233741","title":"NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts","url":"https://stock-news.laohu8.com/highlight/detail?id=2505233741","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505233741?lang=en_us&edition=fundamental","pubTime":"2025-01-20 23:53","pubTimestamp":1737388380,"startTime":"0","endTime":"0","summary":"Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under Medicare Part D for the second round of price negotiations in 2025. Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes  and Wegovy injections for weight management.Any price reduction resulting from the impending negotiations will become effective in 2027.For continued coverage of its semaglutide medicines under Medicare, NVO has until Feb. 28, 2025, to decide if it will participate in negotiations or pay a large tax on U.S. sales of the drugs. Either way, investors anticipate a decline in the company's profit margins resulting in the stock price decline. The Inflation Reduction Act allows Medicare to negotiate the prices of certain prescription drugs to make them more affordable for seniors and people with disabilities.Analysis of th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-stock-down-medicare-selects-155300223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0006306889.USD","LU1035775433.USD","LU0820561818.USD","IE0009355771.USD","NVO","LU0708995401.HKD","LU1868836591.USD","LU1983299246.USD","LU0058720904.USD","LU0943347566.SGD","LU1551013425.SGD","LU0198837287.USD","LU1720051017.SGD","LU1868837136.USD","LU0256863811.USD","LU2237443549.SGD","LU0466842654.USD","LU2237438978.USD","LU0114720955.EUR","LU1712237335.SGD","LU0471298777.SGD","LU1057294990.SGD","IE00B4R5TH58.HKD","SGXZ99366536.SGD","LU2264538146.SGD","BK4566","LLY","LU0672654240.SGD","LU1804176565.USD","IE0002270589.USD","BK4534","BMRN","LU0109391861.USD","LU1280957306.USD","IE00BKVL7J92.USD","LU0238689110.USD","BK4516","LU2361045086.USD","LU0640476718.USD","SG9999001176.SGD","LU2063271972.USD","CSTL","LU0094547139.USD","LU2491050154.USD","LU0096364046.USD","SG9999015945.SGD","IE00BK4W5M84.HKD","LU0320765059.SGD","SG9999015952.SGD","LU1093756168.USD"],"gpt_icon":1},{"id":"2505287123","title":"Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505287123","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505287123?lang=en_us&edition=fundamental","pubTime":"2025-01-20 22:18","pubTimestamp":1737382680,"startTime":"0","endTime":"0","summary":"Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras , in combination with its anti-EGFR antibody, Vectibix , for treating KRAS G12C-mutated metastatic colorectal cancer .The regulatory body approved Lumakras plus Vectibix for treating KRAS G12C-mutated mCRC in adult patients who have previously received fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.Lumakras is presently approved for treating advanced or metastatic non-small cell lung cancer . The drug was approved in the United States in May 2021 and in the EU  in January 2022.In the past year, shares of Amgen have dropped 12.2% compared with the industry’s decline of 14.1%.Lumakras’ approval for the mCRC indication was based on data from the phase III CodeBreaK 300 study, which evaluated Lumakras plus Vectibix versus the investigator's choice of therapy in KRAS G12C–mutated mCRC.Data from the CodeBreaK 300 study also showed that treatment with Lumakras plus Vectibix demonstrated favorable ov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgens-lumakras-gets-fda-nod-141800343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","PFS","CTMX","IE00BJT1NW94.SGD","SG9999001440.SGD","LU2242652126.USD","SOC","IE00B2B36J28.USD","AMGN","LU0289739699.SGD","BK4196","BK4588","LU1023059063.AUD","LU0320765992.SGD","LU1983299246.USD","LU1061106388.HKD","BK4211","IE00BFTCPJ56.SGD","BK4585","IE0002141913.USD","BK4599","CSTL","LU0889565916.HKD","LU1571399168.USD","BK4533","IE0009355771.USD","LU0122379950.USD","LU2242646821.SGD","LU1057294990.SGD","BK4213","BK4139","LU0058720904.USD","BK4195","LU2112291526.USD","BK4534","LU0868494617.USD","LU0109394709.USD","BK4581","VYGR"],"gpt_icon":0},{"id":"2504929191","title":"Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504929191","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504929191?lang=en_us&edition=fundamental","pubTime":"2025-01-17 23:28","pubTimestamp":1737127680,"startTime":"0","endTime":"0","summary":"Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen , its investigational candidate for treating Dravet syndrome, a severe and progressive genetic epilepsy.Zorevunersen is a novel proprietary antisense oligonucleotide with the potential to become the first disease-modifying therapy to address the genetic cause of Dravet syndrome.The FDA granted a Breakthrough Therapy designation to zorevunersen for treating Dravet syndrome in December 2024.In the past year, shares of Stoke Therapeutics have rallied 94.7% against the industry’s decline of 13.6%.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 30.6%.In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have decreased 49.5%.CTMX’s earnings beat estimates in two of the trailing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/good-idea-invest-stoke-therapeutics-152800824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","LENZ","BK4196","VYGR","STOK","CSTL","BK4139"],"gpt_icon":0},{"id":"2504195429","title":"ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2504195429","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504195429?lang=en_us&edition=fundamental","pubTime":"2025-01-17 22:24","pubTimestamp":1737123840,"startTime":"0","endTime":"0","summary":"Tab-cel, the company’s novel T-cell immunotherapy, is already marketed in the EU under the brand name, Ebvallo, by Atara’s partner Pierre Fabre under an exclusive commercialization and license agreement.EBV+ PTLD is a rare hematologic malignancy  with a high mortality rate and occurs after patients undergo transplantation when their T-cell immune responses are compromised by immunosuppression.In the past three months, Atara shares have lost 16.8% compared with the industry’s 12.2% decline.More on the FDA’s CRL Issuance Against ATRA’s Ebvallo. Atara is eligible to receive a $60 million milestone payment from Pierre Fabre upon FDA approval of the Ebvallo BLA, providing a critical cash infusion for the company. Additionally, it will be eligible for substantial double-digit tiered royalties based on net sales and further milestones tied to Ebvallo's commercial performance. However, the FDA's CRL has also delayed the milestone payment, impacting funds the company planned to allocate for sup","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atra-stock-down-fda-issues-142400167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","BMRN","IE0002270589.USD","IE00B19Z3581.USD","BK4196","LU0390134368.USD","BK4121","BK4139","ATRA","CRL","BK4530","IE00B7SZLL34.SGD","BK4585","CSTL","BK4588","IE00B19Z3B42.SGD","BK4566"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":195,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSTL\",params:#limit:5,,,undefined,":[{"date":"2025-05-05","symbol":"CSTL","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.08,"defaultRemindTime":1746475200000,"name":null,"time":"Post Market","dateTimestamp":1746417600000,"actualEps":null},{"market":"US","date":"2025-02-27","symbol":"CSTL","fiscalQuarterEnding":"2024/12","expectedEps":0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":0.32},{"market":"US","date":"2025-01-12","symbol":"CSTL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736658000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-04","symbol":"CSTL","fiscalQuarterEnding":"2024/09","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730696400000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2024-08-05","symbol":"CSTL","fiscalQuarterEnding":"2024/06","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":0.31}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSTL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSTL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5556,"buy":0.4444,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5556,"analysts":9,"updateTime":1702526400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSTL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSTL","date":"2025-04-29","current":31.761841,"percent":0.8125,"low":-703.916349,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"high":155.734424,"avg":-45.836565,"sd":148.870167,"marketCap":579494784},"quantilePoints":[{"date":"2020-05-01","current":92.390956,"twenty":-143.704042,"median":68.845748,"eighty":81.767269,"marketCap":487547076},{"date":"2020-05-08","current":102.692841,"twenty":-142.838448,"median":69.315315,"eighty":83.406552,"marketCap":541910124},{"date":"2020-05-15","current":89.505926,"twenty":-142.421108,"median":70.049766,"eighty":84.306716,"marketCap":644890198},{"date":"2020-05-22","current":90.653132,"twenty":-141.385486,"median":70.663815,"eighty":86.10245,"marketCap":653155813},{"date":"2020-05-29","current":91.848137,"twenty":-139.963439,"median":70.856459,"eighty":88.430421,"marketCap":661765829},{"date":"2020-06-05","current":90.079529,"twenty":-139.808869,"median":71.037061,"eighty":89.171324,"marketCap":649023006},{"date":"2020-06-12","current":88.478221,"twenty":-139.422443,"median":71.891914,"eighty":89.431502,"marketCap":637485584},{"date":"2020-06-19","current":101.300632,"twenty":-137.181173,"median":72.096597,"eighty":89.912228,"marketCap":729871056},{"date":"2020-06-26","current":93.605957,"twenty":-130.766504,"median":72.216999,"eighty":90.734693,"marketCap":674430922},{"date":"2020-07-02","current":102.622433,"twenty":-129.220801,"median":72.241079,"eighty":91.444186,"marketCap":739394631},{"date":"2020-07-10","current":111.372149,"twenty":-123.084358,"median":72.843088,"eighty":91.857697,"marketCap":802436336},{"date":"2020-07-17","current":117.305694,"twenty":-115.1504,"median":73.469177,"eighty":92.281742,"marketCap":845187527},{"date":"2020-07-24","current":106.527432,"twenty":-106.40243,"median":74.167508,"eighty":92.916333,"marketCap":767530147},{"date":"2020-07-31","current":105.654256,"twenty":-102.767312,"median":74.396271,"eighty":93.757226,"marketCap":761238917},{"date":"2020-08-07","current":114.058572,"twenty":-101.783309,"median":74.456472,"eighty":94.202941,"marketCap":821792012},{"date":"2020-08-14","current":114.576879,"twenty":-98.400291,"median":74.981827,"eighty":94.738911,"marketCap":813266685},{"date":"2020-08-21","current":126.944083,"twenty":-97.554536,"median":75.780892,"eighty":96.467657,"marketCap":901049101},{"date":"2020-08-28","current":126.334042,"twenty":-95.952482,"median":76.635745,"eighty":97.420065,"marketCap":896719027},{"date":"2020-09-04","current":133.238602,"twenty":-93.309499,"median":76.98491,"eighty":99.303027,"marketCap":945727595},{"date":"2020-09-11","current":134.763705,"twenty":-92.601993,"median":77.514678,"eighty":100.272889,"marketCap":956552781},{"date":"2020-09-18","current":141.52962,"twenty":-91.068613,"median":78.020365,"eighty":102.449512,"marketCap":1004577242},{"date":"2020-09-25","current":137.592079,"twenty":-89.595469,"median":78.419535,"eighty":103.419182,"marketCap":976628580},{"date":"2020-10-02","current":142.611057,"twenty":-88.909949,"median":79.699487,"eighty":106.169125,"marketCap":1012253283},{"date":"2020-10-09","current":152.122158,"twenty":-87.950343,"median":80.235758,"eighty":108.912247,"marketCap":1079763078},{"date":"2020-10-16","current":138.5626,"twenty":-87.36482,"median":81.186932,"eighty":110.294181,"marketCap":983517335},{"date":"2020-10-23","current":143.747953,"twenty":-87.250969,"median":82.192491,"eighty":112.350606,"marketCap":1020322967},{"date":"2020-10-30","current":128.746478,"twenty":-87.169646,"median":82.764196,"eighty":114.265895,"marketCap":913842503},{"date":"2020-11-06","current":143.359744,"twenty":-86.063659,"median":84.023258,"eighty":116.079799,"marketCap":1017567465},{"date":"2020-11-13","current":-300.218351,"twenty":-87.950343,"median":82.764196,"eighty":115.530762,"marketCap":1002729291},{"date":"2020-11-20","current":-286.626257,"twenty":-92.601993,"median":82.192491,"eighty":115.132049,"marketCap":957331698},{"date":"2020-11-27","current":-265.105442,"twenty":-97.570801,"median":81.439776,"eighty":114.888032,"marketCap":885452175},{"date":"2020-12-04","current":-309.99512,"twenty":-109.964358,"median":80.259839,"eighty":114.369556,"marketCap":1035383700},{"date":"2020-12-11","current":-356.136701,"twenty":-134.615305,"median":79.885626,"eighty":113.96642,"marketCap":1189496581},{"date":"2020-12-18","current":-450.787075,"twenty":-141.029974,"median":78.954401,"eighty":113.756623,"marketCap":1505628832},{"date":"2020-12-24","current":-515.732815,"twenty":-143.704042,"median":78.164847,"eighty":113.491008,"marketCap":1722547602},{"date":"2020-12-31","current":-485.646593,"twenty":-146.146252,"median":77.835827,"eighty":112.857956,"marketCap":1622059619},{"date":"2021-01-08","current":-575.760614,"twenty":-151.556214,"median":77.346115,"eighty":112.012372,"marketCap":1923040451},{"date":"2021-01-15","current":-536.200125,"twenty":-153.642914,"median":76.720026,"eighty":111.384472,"marketCap":1790908417},{"date":"2021-01-22","current":-572.578418,"twenty":-155.265902,"median":76.491263,"eighty":111.374614,"marketCap":1912411915},{"date":"2021-01-29","current":-483.332268,"twenty":-167.600615,"median":75.585094,"eighty":110.83863,"marketCap":1614329774},{"date":"2021-02-05","current":-671.081866,"twenty":-169.640943,"median":74.685236,"eighty":110.157158,"marketCap":2241413434},{"date":"2021-02-12","current":-690.970595,"twenty":-171.341217,"median":74.456472,"eighty":109.561717,"marketCap":2307841788},{"date":"2021-02-19","current":-656.255723,"twenty":-173.845257,"median":74.33607,"eighty":109.348881,"marketCap":2191894116},{"date":"2021-02-26","current":-550.230719,"twenty":-178.868792,"median":74.167508,"eighty":109.144161,"marketCap":1837770601},{"date":"2021-03-05","current":-498.881637,"twenty":-200.184042,"median":73.01165,"eighty":108.912247,"marketCap":1666264669},{"date":"2021-03-12","current":-155.908697,"twenty":-197.741831,"median":72.590244,"eighty":108.442961,"marketCap":1603365036},{"date":"2021-03-19","current":-161.592235,"twenty":-187.710216,"median":72.241079,"eighty":107.618901,"marketCap":1661814548},{"date":"2021-03-26","current":-145.658896,"twenty":-181.094605,"median":72.144757,"eighty":106.811214,"marketCap":1497956087},{"date":"2021-04-01","current":-172.643561,"twenty":-179.425246,"median":72.072517,"eighty":106.28856,"marketCap":1775466377},{"date":"2021-04-09","current":-168.830246,"twenty":-179.507526,"median":71.807633,"eighty":105.852599,"marketCap":1736250252},{"date":"2021-04-16","current":-159.114795,"twenty":-178.054894,"median":70.96482,"eighty":105.703373,"marketCap":1636336556},{"date":"2021-04-23","current":-164.142541,"twenty":-177.570402,"median":70.844418,"eighty":105.135102,"marketCap":1688041893},{"date":"2021-04-30","current":-168.180083,"twenty":-176.766636,"median":70.627694,"eighty":103.731578,"marketCap":1729563976},{"date":"2021-05-07","current":-146.959621,"twenty":-175.143647,"median":69.495918,"eighty":102.75377,"marketCap":1511332740},{"date":"2021-05-14","current":-91.341496,"twenty":-173.860714,"median":69.134713,"eighty":102.6761,"marketCap":1382362194},{"date":"2021-05-21","current":-95.480588,"twenty":-173.49996,"median":68.484543,"eighty":102.639567,"marketCap":1445003222},{"date":"2021-05-28","current":-99.222328,"twenty":-172.874456,"median":67.172163,"eighty":102.507152,"marketCap":1501630711},{"date":"2021-06-04","current":-104.801825,"twenty":-172.506749,"median":65.944065,"eighty":102.127511,"marketCap":1586070816},{"date":"2021-06-11","current":-119.023747,"twenty":-171.940864,"median":65.462458,"eighty":101.207424,"marketCap":1801305386},{"date":"2021-06-18","current":-121.623097,"twenty":-171.761303,"median":65.089212,"eighty":100.776014,"marketCap":1840643952},{"date":"2021-06-25","current":-121.490646,"twenty":-171.341217,"median":64.848409,"eighty":100.452102,"marketCap":1838639439},{"date":"2021-07-02","current":-117.450892,"twenty":-171.339369,"median":64.547404,"eighty":99.99422,"marketCap":1777501796},{"date":"2021-07-09","current":-121.507203,"twenty":-171.331975,"median":62.921979,"eighty":99.596394,"marketCap":1838890003},{"date":"2021-07-16","current":-107.599851,"twenty":-170.645651,"median":-30.05226,"eighty":99.432751,"marketCap":1628416150},{"date":"2021-07-23","current":-113.907828,"twenty":-170.627605,"median":-66.775802,"eighty":99.270596,"marketCap":1723881076},{"date":"2021-07-30","current":-115.646247,"twenty":-170.259225,"median":-79.533458,"eighty":98.781094,"marketCap":1750190308},{"date":"2021-08-06","current":-118.907852,"twenty":-170.259225,"median":-80.976934,"eighty":98.358362,"marketCap":1799551438},{"date":"2021-08-13","current":-71.922702,"twenty":-169.486373,"median":-79.89941,"eighty":97.576447,"marketCap":1621785000},{"date":"2021-08-20","current":-73.898232,"twenty":-168.830246,"median":-78.110313,"eighty":97.380969,"marketCap":1666331236},{"date":"2021-08-27","current":-82.916473,"twenty":-168.790806,"median":-79.533458,"eighty":97.12033,"marketCap":1869683545},{"date":"2021-09-03","current":-85.70677,"twenty":-168.558951,"median":-80.554542,"eighty":96.729373,"marketCap":1932601958},{"date":"2021-09-10","current":-83.128535,"twenty":-168.255857,"median":-81.000595,"eighty":96.620807,"marketCap":1874465345},{"date":"2021-09-17","current":-86.298313,"twenty":-167.864896,"median":-81.677581,"eighty":96.467657,"marketCap":1945940661},{"date":"2021-09-24","current":-80.851653,"twenty":-167.600615,"median":-81.817096,"eighty":96.094956,"marketCap":1823123920},{"date":"2021-10-01","current":-72.927209,"twenty":-167.548158,"median":-81.052554,"eighty":95.725323,"marketCap":1644435629},{"date":"2021-10-08","current":-68.418088,"twenty":-166.747019,"median":-80.939604,"eighty":95.341474,"marketCap":1542759474},{"date":"2021-10-15","current":-70.962839,"twenty":-166.488822,"median":-80.193143,"eighty":94.738911,"marketCap":1600141066},{"date":"2021-10-22","current":-70.014138,"twenty":-166.318802,"median":-79.455917,"eighty":94.477414,"marketCap":1578748806},{"date":"2021-10-29","current":-69.590013,"twenty":-165.92895,"median":-79.054701,"eighty":94.395866,"marketCap":1569185207},{"date":"2021-11-05","current":-66.46488,"twenty":-165.628697,"median":-75.845859,"eighty":94.279373,"marketCap":1498716585},{"date":"2021-11-12","current":-43.948833,"twenty":-165.400692,"median":-74.221907,"eighty":94.202941,"marketCap":1307521726},{"date":"2021-11-19","current":-40.394148,"twenty":-165.136289,"median":-73.228561,"eighty":94.032207,"marketCap":1201766292},{"date":"2021-11-26","current":-36.669382,"twenty":-164.802892,"median":-72.66492,"eighty":93.911867,"marketCap":1090950790},{"date":"2021-12-03","current":-35.232201,"twenty":-164.332488,"median":-72.525406,"eighty":93.857997,"marketCap":1048193210},{"date":"2021-12-10","current":-35.043363,"twenty":-164.069675,"median":-71.699478,"eighty":93.782419,"marketCap":1042575102},{"date":"2021-12-17","current":-36.565484,"twenty":-163.125113,"median":-70.962839,"eighty":93.656387,"marketCap":1087859706},{"date":"2021-12-23","current":-36.824936,"twenty":-162.260438,"median":-70.538714,"eighty":93.390391,"marketCap":1095578673},{"date":"2021-12-31","current":-37.07574,"twenty":-161.75254,"median":-70.326651,"eighty":93.033305,"marketCap":1103040341},{"date":"2022-01-07","current":-33.80664,"twenty":-160.853861,"median":-70.081106,"eighty":92.949516,"marketCap":1005781361},{"date":"2022-01-14","current":-31.297701,"twenty":-159.513129,"median":-69.768592,"eighty":92.804142,"marketCap":931137898},{"date":"2022-01-21","current":-28.661836,"twenty":-159.163373,"median":-69.221694,"eighty":92.613304,"marketCap":852718272},{"date":"2022-01-28","current":-32.764914,"twenty":-159.153657,"median":-68.462733,"eighty":92.417037,"marketCap":974788953},{"date":"2022-02-04","current":-36.620613,"twenty":-159.037071,"median":-68.077672,"eighty":92.363653,"marketCap":1089499863},{"date":"2022-02-11","current":-37.07272,"twenty":-158.52701,"median":-67.458226,"eighty":92.230539,"marketCap":1102950479},{"date":"2022-02-18","current":-33.933566,"twenty":-157.725045,"median":-66.676942,"eighty":92.12856,"marketCap":1009557525},{"date":"2022-02-25","current":-38.121947,"twenty":-157.70385,"median":-56.620469,"eighty":92.103044,"marketCap":1134166058},{"date":"2022-03-04","current":-34.317143,"twenty":-156.502465,"median":-46.976268,"eighty":91.895938,"marketCap":1073852040},{"date":"2022-03-11","current":-32.441312,"twenty":-155.908697,"median":-44.969316,"eighty":91.848137,"marketCap":1015153549},{"date":"2022-03-18","current":-36.6396,"twenty":-155.213239,"median":-44.561123,"eighty":91.680837,"marketCap":1146526362},{"date":"2022-03-25","current":-34.406468,"twenty":-154.956761,"median":-41.163763,"eighty":91.549188,"marketCap":1076647206},{"date":"2022-04-01","current":-37.337961,"twenty":-153.952054,"median":-39.575131,"eighty":91.549188,"marketCap":1168379479},{"date":"2022-04-08","current":-26.594568,"twenty":-153.917029,"median":-38.48489,"eighty":91.417935,"marketCap":832197215},{"date":"2022-04-14","current":-21.064522,"twenty":-153.883221,"median":-38.135515,"eighty":91.392618,"marketCap":659151015},{"date":"2022-04-22","current":-18.65924,"twenty":-153.705343,"median":-38.019584,"eighty":91.277765,"marketCap":583884947},{"date":"2022-04-29","current":-18.194999,"twenty":-153.646928,"median":-37.870138,"eighty":90.837881,"marketCap":569357910},{"date":"2022-05-06","current":-17.742098,"twenty":-153.581085,"median":-37.62719,"eighty":90.669444,"marketCap":555185744},{"date":"2022-05-13","current":-10.02426,"twenty":-153.127806,"median":-37.342022,"eighty":90.431678,"marketCap":517602654},{"date":"2022-05-20","current":-11.01092,"twenty":-152.745149,"median":-37.268917,"eighty":90.138886,"marketCap":568548831},{"date":"2022-05-27","current":-11.534765,"twenty":-152.15131,"median":-37.07423,"eighty":89.945688,"marketCap":595597574},{"date":"2022-06-03","current":-9.714021,"twenty":-151.992333,"median":-36.988631,"eighty":89.740147,"marketCap":501583495},{"date":"2022-06-10","current":-9.890877,"twenty":-151.80124,"median":-36.824936,"eighty":89.553726,"marketCap":510715451},{"date":"2022-06-17","current":-8.14483,"twenty":-151.608171,"median":-36.696416,"eighty":89.491586,"marketCap":420558272},{"date":"2022-06-24","current":-12.130705,"twenty":-151.344402,"median":-36.658551,"eighty":89.461816,"marketCap":626368976},{"date":"2022-07-01","current":-11.458757,"twenty":-150.793512,"median":-36.620613,"eighty":89.366342,"marketCap":591672918},{"date":"2022-07-08","current":-13.133538,"twenty":-150.278593,"median":-36.428467,"eighty":89.249147,"marketCap":678150213},{"date":"2022-07-15","current":-12.588852,"twenty":-149.603714,"median":-36.089951,"eighty":89.1582,"marketCap":650025379},{"date":"2022-07-22","current":-12.950279,"twenty":-149.104402,"median":-35.730106,"eighty":89.071615,"marketCap":668687652},{"date":"2022-07-29","current":-14.23309,"twenty":-147.282584,"median":-35.640177,"eighty":88.843853,"marketCap":734925580},{"date":"2022-08-05","current":-15.556624,"twenty":-147.050863,"median":-35.579565,"eighty":88.468661,"marketCap":803266299},{"date":"2022-08-12","current":-20.060215,"twenty":-146.936061,"median":-35.460837,"eighty":88.420861,"marketCap":892519093},{"date":"2022-08-19","current":-18.842653,"twenty":-146.702706,"median":-35.366658,"eighty":88.334821,"marketCap":838347339},{"date":"2022-08-26","current":-18.287067,"twenty":-146.099345,"median":-35.166981,"eighty":87.890279,"marketCap":813628189},{"date":"2022-09-02","current":-16.543472,"twenty":-145.861154,"median":-35.147161,"eighty":86.833894,"marketCap":736052134},{"date":"2022-09-09","current":-17.335478,"twenty":-145.658896,"median":-35.015504,"eighty":86.661813,"marketCap":771290071},{"date":"2022-09-16","current":-16.04699,"twenty":-144.832405,"median":-34.913637,"eighty":86.238683,"marketCap":713962681},{"date":"2022-09-23","current":-14.569367,"twenty":-144.059553,"median":-34.541755,"eighty":85.557518,"marketCap":648220261},{"date":"2022-09-30","current":-15.414567,"twenty":-143.904983,"median":-34.361806,"eighty":85.203906,"marketCap":685824925},{"date":"2022-10-07","current":-15.733734,"twenty":-143.10859,"median":-34.256358,"eighty":84.606403,"marketCap":700025288},{"date":"2022-10-14","current":-13.014907,"twenty":-142.900276,"median":-33.942644,"eighty":84.37758,"marketCap":579059235},{"date":"2022-10-21","current":-12.701651,"twenty":-142.591135,"median":-33.780695,"eighty":84.023258,"marketCap":565121842},{"date":"2022-10-28","current":-13.848286,"twenty":-141.740998,"median":-33.572754,"eighty":83.567141,"marketCap":616137960},{"date":"2022-11-04","current":-10.918859,"twenty":-139.963439,"median":-33.417462,"eighty":82.764196,"marketCap":578153577},{"date":"2022-11-11","current":-11.152763,"twenty":-139.808869,"median":-32.603113,"eighty":82.764196,"marketCap":590538818},{"date":"2022-11-18","current":-10.45105,"twenty":-139.422443,"median":-31.297701,"eighty":82.306669,"marketCap":553383096},{"date":"2022-11-25","current":-10.585421,"twenty":-137.629427,"median":-30.939428,"eighty":82.215327,"marketCap":560498021},{"date":"2022-12-02","current":-12.795071,"twenty":-137.051739,"median":-30.146712,"eighty":81.917812,"marketCap":677499018},{"date":"2022-12-09","current":-11.107973,"twenty":-132.017079,"median":-29.830488,"eighty":81.521649,"marketCap":588167176},{"date":"2022-12-16","current":-11.978894,"twenty":-129.220801,"median":-29.148408,"eighty":81.035226,"marketCap":634282434},{"date":"2022-12-23","current":-11.560852,"twenty":-127.462725,"median":-28.661836,"eighty":80.413953,"marketCap":612147110},{"date":"2022-12-30","current":-11.715129,"twenty":-126.444312,"median":-28.295032,"eighty":80.255022,"marketCap":620316099},{"date":"2023-01-06","current":-11.346854,"twenty":-125.431062,"median":-25.10852,"eighty":80.129804,"marketCap":600815932},{"date":"2023-01-13","current":-13.541575,"twenty":-124.480726,"median":-21.758823,"eighty":79.936775,"marketCap":717026382},{"date":"2023-01-20","current":-13.257903,"twenty":-124.252248,"median":-20.468425,"eighty":79.81117,"marketCap":702005984},{"date":"2023-01-27","current":-12.939395,"twenty":-123.914499,"median":-20.219799,"eighty":79.508532,"marketCap":685140976},{"date":"2023-02-03","current":-14.084034,"twenty":-123.669464,"median":-19.981754,"eighty":79.275321,"marketCap":745749600},{"date":"2023-02-10","current":-13.1733,"twenty":-123.391317,"median":-19.773366,"eighty":78.392678,"marketCap":697526216},{"date":"2023-02-17","current":-12.939395,"twenty":-122.237123,"median":-19.352035,"eighty":78.237088,"marketCap":685140976},{"date":"2023-02-24","current":-12.123218,"twenty":-121.646854,"median":-19.194328,"eighty":78.044446,"marketCap":641924391},{"date":"2023-03-03","current":-9.769225,"twenty":-121.623097,"median":-18.990416,"eighty":77.996285,"marketCap":655886202},{"date":"2023-03-10","current":-7.706921,"twenty":-121.507203,"median":-18.763163,"eighty":77.67537,"marketCap":517427243},{"date":"2023-03-17","current":-8.470884,"twenty":-121.490646,"median":-18.651096,"eighty":77.514678,"marketCap":568718182},{"date":"2023-03-24","current":-8.910261,"twenty":-121.407864,"median":-18.327158,"eighty":77.346115,"marketCap":598217116},{"date":"2023-03-31","current":-8.993387,"twenty":-120.530377,"median":-18.243867,"eighty":76.98491,"marketCap":603797995},{"date":"2023-04-06","current":-8.827136,"twenty":-120.25223,"median":-18.109752,"eighty":76.792267,"marketCap":592636236},{"date":"2023-04-14","current":-9.233586,"twenty":-119.573419,"median":-17.654644,"eighty":76.705578,"marketCap":619924514},{"date":"2023-04-21","current":-9.5476,"twenty":-119.262158,"median":-17.35912,"eighty":76.599624,"marketCap":641006751},{"date":"2023-04-28","current":-8.804302,"twenty":-119.063482,"median":-17.187715,"eighty":76.440694,"marketCap":591103228},{"date":"2023-05-05","current":-8.18984,"twenty":-118.984012,"median":-16.797623,"eighty":75.90611,"marketCap":587367135},{"date":"2023-05-12","current":-8.442866,"twenty":-118.921097,"median":-16.759205,"eighty":75.624254,"marketCap":605513871},{"date":"2023-05-19","current":-8.747984,"twenty":-118.854872,"median":-16.543472,"eighty":75.272328,"marketCap":627396699},{"date":"2023-05-26","current":-9.369385,"twenty":-118.099901,"median":-16.162244,"eighty":74.854441,"marketCap":671962947},{"date":"2023-06-02","current":-7.832628,"twenty":-117.894602,"median":-15.796084,"eighty":74.668379,"marketCap":561748214},{"date":"2023-06-09","current":-5.33214,"twenty":-117.642945,"median":-15.68645,"eighty":74.514265,"marketCap":382415768},{"date":"2023-06-16","current":-4.986091,"twenty":-117.464137,"median":-15.580163,"eighty":74.456472,"marketCap":357597438},{"date":"2023-06-23","current":-4.930276,"twenty":-117.424402,"median":-15.417523,"eighty":74.456472,"marketCap":353594482},{"date":"2023-06-30","current":-4.933997,"twenty":-117.219102,"median":-15.257939,"eighty":74.432392,"marketCap":353861345},{"date":"2023-07-07","current":-4.941439,"twenty":-116.556848,"median":-15.108846,"eighty":74.33607,"marketCap":354395073},{"date":"2023-07-14","current":-6.02796,"twenty":-116.507179,"median":-14.859223,"eighty":74.263829,"marketCap":432319291},{"date":"2023-07-21","current":-6.214009,"twenty":-115.646247,"median":-14.557546,"eighty":74.167508,"marketCap":445662479},{"date":"2023-07-28","current":-5.894006,"twenty":-115.613135,"median":-14.258542,"eighty":74.167508,"marketCap":422712195},{"date":"2023-08-04","current":-5.663815,"twenty":-115.513796,"median":-14.240825,"eighty":73.926704,"marketCap":503218594},{"date":"2023-08-11","current":-5.280594,"twenty":-114.553527,"median":-14.178591,"eighty":73.01165,"marketCap":469170240},{"date":"2023-08-18","current":-5.208175,"twenty":-113.907828,"median":-14.052198,"eighty":72.867168,"marketCap":462735905},{"date":"2023-08-25","current":-5.64571,"twenty":-113.791934,"median":-13.89557,"eighty":72.843088,"marketCap":501610010},{"date":"2023-09-01","current":-6.013843,"twenty":-113.659483,"median":-13.834522,"eighty":72.3374,"marketCap":534317879},{"date":"2023-09-08","current":-5.66985,"twenty":-113.552925,"median":-13.793063,"eighty":72.260343,"marketCap":503754789},{"date":"2023-09-15","current":-5.310769,"twenty":-113.447412,"median":-13.581503,"eighty":72.241079,"marketCap":471851212},{"date":"2023-09-22","current":-5.027126,"twenty":-113.123056,"median":-13.47439,"eighty":72.241079,"marketCap":446650068},{"date":"2023-09-29","current":-5.247402,"twenty":-111.576691,"median":-13.437064,"eighty":72.20255,"marketCap":466221169},{"date":"2023-10-06","current":-4.483979,"twenty":-111.103179,"median":-13.330065,"eighty":72.115861,"marketCap":398392558},{"date":"2023-10-13","current":-3.678311,"twenty":-110.692581,"median":-13.257903,"eighty":72.096597,"marketCap":326810584},{"date":"2023-10-20","current":-3.862378,"twenty":-109.828339,"median":-13.190718,"eighty":72.058068,"marketCap":343164518},{"date":"2023-10-27","current":-3.946867,"twenty":-109.228998,"median":-13.161054,"eighty":72.033988,"marketCap":350671242},{"date":"2023-11-03","current":-5.912031,"twenty":-107.583295,"median":-13.139027,"eighty":71.942483,"marketCap":446381971},{"date":"2023-11-10","current":-6.105341,"twenty":-107.470712,"median":-13.073766,"eighty":71.720944,"marketCap":460977687},{"date":"2023-11-17","current":-6.860935,"twenty":-106.821702,"median":-13.014907,"eighty":71.306761,"marketCap":518028049},{"date":"2023-11-24","current":-7.085475,"twenty":-104.967388,"median":-12.997175,"eighty":71.037061,"marketCap":534981694},{"date":"2023-12-01","current":-7.12468,"twenty":-104.801825,"median":-12.950279,"eighty":70.892579,"marketCap":537941854},{"date":"2023-12-08","current":-6.878756,"twenty":-104.621466,"median":-12.939395,"eighty":70.868499,"marketCap":519373576},{"date":"2023-12-15","current":-7.345656,"twenty":-102.303773,"median":-12.93329,"eighty":70.844418,"marketCap":554626394},{"date":"2023-12-22","current":-7.766222,"twenty":-101.653193,"median":-12.899374,"eighty":70.675856,"marketCap":586380840},{"date":"2023-12-29","current":-7.994326,"twenty":-101.138387,"median":-12.831107,"eighty":70.661407,"marketCap":603603591},{"date":"2024-01-05","current":-7.242296,"twenty":-100.480612,"median":-12.765211,"eighty":70.642143,"marketCap":546822335},{"date":"2024-01-12","current":-7.345656,"twenty":-99.17597,"median":-12.686153,"eighty":70.492844,"marketCap":554626394},{"date":"2024-01-19","current":-6.957166,"twenty":-98.990539,"median":-12.535401,"eighty":70.049766,"marketCap":525293896},{"date":"2024-01-26","current":-7.356348,"twenty":-98.377953,"median":-12.367076,"eighty":69.495918,"marketCap":555433710},{"date":"2024-02-02","current":-8.439841,"twenty":-98.245502,"median":-12.314821,"eighty":69.375516,"marketCap":637241776},{"date":"2024-02-09","current":-8.500431,"twenty":-97.897818,"median":-12.148101,"eighty":69.255114,"marketCap":641816569},{"date":"2024-02-16","current":-8.867536,"twenty":-97.587065,"median":-12.126962,"eighty":69.014311,"marketCap":669534434},{"date":"2024-02-23","current":-8.682202,"twenty":-97.554536,"median":-12.050186,"eighty":68.879461,"marketCap":655540949},{"date":"2024-03-01","current":-8.626783,"twenty":-97.496408,"median":-11.968941,"eighty":68.556784,"marketCap":495746692},{"date":"2024-03-08","current":-9.911724,"twenty":-97.444174,"median":-11.921994,"eighty":68.446014,"marketCap":569587147},{"date":"2024-03-15","current":-9.219098,"twenty":-97.381259,"median":-11.8495,"eighty":67.954775,"marketCap":529784671},{"date":"2024-03-22","current":-10.07891,"twenty":-97.328279,"median":-11.779827,"eighty":66.774837,"marketCap":579194641},{"date":"2024-03-28","current":-10.164891,"twenty":-96.980595,"median":-11.747478,"eighty":66.394368,"marketCap":584135638},{"date":"2024-04-05","current":-10.145784,"twenty":-96.034573,"median":-11.715129,"eighty":65.869416,"marketCap":583037638},{"date":"2024-04-12","current":-9.975623,"twenty":-95.509954,"median":-11.674233,"eighty":65.541923,"marketCap":573259148},{"date":"2024-04-19","current":-9.21713,"twenty":-93.841259,"median":-11.590712,"eighty":65.486538,"marketCap":529671590},{"date":"2024-04-26","current":-9.365948,"twenty":-92.601993,"median":-11.540343,"eighty":65.296304,"marketCap":538223579},{"date":"2024-05-03","current":-20.460076,"twenty":-92.472226,"median":-11.516062,"eighty":65.156637,"marketCap":630088496},{"date":"2024-05-10","current":-21.891395,"twenty":-91.785206,"median":-11.553387,"eighty":65.07958,"marketCap":674167408},{"date":"2024-05-17","current":-21.712105,"twenty":-90.954077,"median":-11.630526,"eighty":64.939914,"marketCap":668645972},{"date":"2024-05-24","current":-21.281807,"twenty":-90.477253,"median":-11.705647,"eighty":64.858041,"marketCap":655394524},{"date":"2024-05-31","current":-21.70314,"twenty":-90.243501,"median":-11.725082,"eighty":64.752087,"marketCap":668369900},{"date":"2024-06-07","current":-20.645325,"twenty":-89.767451,"median":-11.754943,"eighty":64.597973,"marketCap":635793424},{"date":"2024-06-14","current":-20.331566,"twenty":-89.137652,"median":-11.784803,"eighty":64.569077,"marketCap":626130910},{"date":"2024-06-21","current":-18.888276,"twenty":-88.682246,"median":-11.8495,"eighty":64.511283,"marketCap":581683345},{"date":"2024-06-28","current":-18.968957,"twenty":-88.19431,"median":-11.87936,"eighty":63.91409,"marketCap":584167992},{"date":"2024-07-05","current":-19.049638,"twenty":-87.429878,"median":-11.962718,"eighty":62.979772,"marketCap":586652638},{"date":"2024-07-12","current":-16.575426,"twenty":-87.283498,"median":-11.973917,"eighty":62.661912,"marketCap":510456813},{"date":"2024-07-15","current":-16.629213,"twenty":-87.267233,"median":-11.978894,"eighty":62.498165,"marketCap":512113244},{"date":"2024-08-02","current":-20.654289,"twenty":-86.610826,"median":-11.921994,"eighty":63.018301,"marketCap":636069496},{"date":"2024-08-09","current":-249.174378,"twenty":-87.299762,"median":-11.921994,"eighty":63.018301,"marketCap":772191398},{"date":"2024-08-16","current":-242.909218,"twenty":-92.450772,"median":-11.921994,"eighty":63.018301,"marketCap":752775666},{"date":"2024-08-23","current":-246.399807,"twenty":-97.318345,"median":-11.921994,"eighty":63.018301,"marketCap":763593002},{"date":"2024-08-30","current":-266.627325,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":826278080},{"date":"2024-09-06","current":-263.852754,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":817679684},{"date":"2024-09-13","current":-274.593029,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":850963796},{"date":"2024-09-20","current":-273.250494,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":846803282},{"date":"2024-09-27","current":-250.606415,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":776629280},{"date":"2024-10-04","current":-254.365511,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":788278719},{"date":"2024-10-11","current":-253.291484,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":784950308},{"date":"2024-10-18","current":-295.894574,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":916977285},{"date":"2024-10-25","current":-284.617286,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":882028968},{"date":"2024-10-31","current":-309.140913,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":958027690},{"date":"2024-11-08","current":153.567604,"twenty":-91.563351,"median":-11.784803,"eighty":64.853225,"marketCap":932923196},{"date":"2024-11-15","current":142.134171,"twenty":-90.404405,"median":-11.754943,"eighty":65.240919,"marketCap":863465089},{"date":"2024-11-22","current":133.144173,"twenty":-90.404405,"median":-11.754943,"eighty":65.474498,"marketCap":808850852},{"date":"2024-11-29","current":139.598531,"twenty":-90.404405,"median":-11.754943,"eighty":66.977112,"marketCap":848061074},{"date":"2024-12-06","current":148.265811,"twenty":-90.404405,"median":-11.754943,"eighty":69.332172,"marketCap":900714800},{"date":"2024-12-13","current":134.250635,"twenty":-90.404405,"median":-11.754943,"eighty":70.85405,"marketCap":815572605},{"date":"2024-12-20","current":124.891816,"twenty":-90.404405,"median":-11.754943,"eighty":71.990643,"marketCap":758717784},{"date":"2024-12-27","current":124.937919,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":758997857},{"date":"2025-01-03","current":129.271559,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":785324720},{"date":"2025-01-10","current":150.847554,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":916398888},{"date":"2025-01-17","current":115.671306,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":702703182},{"date":"2025-01-24","current":122.171766,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":742193476},{"date":"2025-01-31","current":130.101405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":790366034},{"date":"2025-02-07","current":128.303405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":779443186},{"date":"2025-02-14","current":127.289149,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":773281580},{"date":"2025-02-21","current":120.558176,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":732390921},{"date":"2025-02-28","current":38.806499,"twenty":-90.477253,"median":-11.764897,"eighty":76.356928,"marketCap":708024569},{"date":"2025-03-07","current":32.178981,"twenty":-90.550101,"median":-11.77485,"eighty":73.454249,"marketCap":587105504},{"date":"2025-03-14","current":29.318974,"twenty":-90.550101,"median":-11.77485,"eighty":33.288601,"marketCap":534924684},{"date":"2025-03-21","current":31.366301,"twenty":-90.550101,"median":-11.77485,"eighty":31.49758,"marketCap":572278167},{"date":"2025-03-28","current":31.413187,"twenty":-90.550101,"median":-11.77485,"eighty":31.375678,"marketCap":573133590},{"date":"2025-04-04","current":29.990998,"twenty":-90.550101,"median":-11.77485,"eighty":31.063109,"marketCap":547185751},{"date":"2025-04-11","current":30.162911,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":550322303},{"date":"2025-04-17","current":33.226087,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":606209957},{"date":"2025-04-25","current":33.089862,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":603724531},{"date":"2025-04-29","current":31.761841,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":579494784}],"updateTime":1746076395355}}}